Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
PCSK9	255738	RG-7652	CHEMBL2109539	inhibitor	ChemblInteractions
PCSK9	255738	BOCOCIZUMAB	CHEMBL3137349	inhibitor	GuideToPharmacologyInteractions, ChemblInteractions
PCSK9	255738	EVOLOCUMAB	CHEMBL2364655	inhibitor	GuideToPharmacologyInteractions, ChemblInteractions
PCSK9	255738	Alirocumab	CHEMBL2109540	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank	26455563

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
PCSK9	rs7552841	CT + TT	atorvastatin	efficacy	no	No significant difference in the % change in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) or triglycerides (TG) were seen between the two genotype groups. Additionally, no significant differences in the basal levels or post-treatment levels were seen. 10 mg/day atorvastatin for 4 weeks.	Genotypes CT + TT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.	26408409	1447674967
PCSK9	rs11591147	T	hmg coa reductase inhibitors	efficacy	yes	There was a 55.6% greater reduction in low-density lipoprotein cholesterol (LDL-C) in carriers of the T alleles as compared to those with the GG genotype. Note that carriers of the T allele were also associated with significantly decreased LDL-C levels at baseline (p=0.00022), though the result for response to statins was adjusted for this association. A p-value <0.0045 was considered statistically significant. The authors do not specify the composition of T allele carriers (i.e. heterozygotes, homozygotes, or both).	Allele T is associated with increased response to hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype GG.	26902539	1447947045